Literature DB >> 20573389

Years of potential life lost and productivity losses from male urogenital cancer deaths--United States, 2004.

Chunyu Li1, Donatus U Ekwueme, Sun Hee Rim, Florence K Tangka.   

Abstract

OBJECTIVES: To estimate years of potential life lost (YPLL) and productivity losses due to deaths from male urogenital cancers in the United States in 2004.
METHODS: To estimate YPLL, we applied a life expectancy method using 2004 national mortality data and life tables. To estimate lifetime productivity losses, we used human capital approach accounting for both the market value and the imputed value of housekeeping services. We calculated results for age and racial/ethnic groups and for 8 categories of male urogenital cancers.
RESULTS: In 2004, deaths from urological cancers accounted for 244,080 YPLL, with an average of 14.4 YPLL per death, and deaths from genital cancers accounted for 309,921 YPLL, with an average of 10.5 YPLL per death. Kidney cancer accounted for 42.7% YPLL from male urological cancers, and prostate cancer accounted for 94.2% of the YPLL from male genital cancers. Testicular cancer had the highest average number of YPLL per death (37.9). Non-Hispanic whites accounted for 77.9% of the YPLL from male urogenital cancer deaths. Overall, urogenital cancers had the largest relative contribution to YPLL among men aged ≥50 years. In 2004, the estimated lifetime productivity loss because of deaths from male urogenital cancer was $10.4 billion USD, 10.6% of the estimated $97.9 billion USD loss because of deaths from all cancers among US men.
CONCLUSIONS: Urogenital cancers impose a considerable health and economic burden in terms of premature deaths and productivity losses in men in the United States, particularly among the elderly and non-Hispanic whites and blacks. Published by Elsevier Inc.

Entities:  

Mesh:

Year:  2010        PMID: 20573389     DOI: 10.1016/j.urology.2010.04.030

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  15 in total

1.  Quantifying the burden of primary central nervous system malignancy.

Authors:  David Schiff
Journal:  Neuro Oncol       Date:  2015-11-20       Impact factor: 12.300

2.  Recent developments in the management of germ cell tumors.

Authors:  Pavlos Msaouel; Mehmet A Bilen; Miao Zhang; Matthew Campbell; Jennifer Wang; Shi-Ming Tu
Journal:  Curr Opin Oncol       Date:  2017-05       Impact factor: 3.645

3.  Years of Life and Productivity Loss Because of Adult Sudden Unexpected Death in the United States.

Authors:  Mojtaba Mirzaei; Golsa Joodi; Brittany Bogle; Sarah Chen; Ross J Simpson
Journal:  Med Care       Date:  2019-07       Impact factor: 2.983

4.  Economic burden of cancer in the United States: estimates, projections, and future research.

Authors:  K Robin Yabroff; Jennifer Lund; Deanna Kepka; Angela Mariotto
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2011-10       Impact factor: 4.254

5.  Regional trends in average years of potential life lost (AYPLL) secondary to prostate cancer deaths among Caucasians and African Americans treated by surgery or radiation.

Authors:  Mohamed H Kamel; Milan Bimali; Mahmoud I Khalil; Ehab Eltahawy; LJoseph Su; Nabil K Bissada; Rodney Davis
Journal:  Int Urol Nephrol       Date:  2019-03-06       Impact factor: 2.370

Review 6.  Epidemiology of renal cancer in developing countries: Review of the literature.

Authors:  Mauricio Medina-Rico; Hugo López Ramos; Manuel Lobo; Jorge Romo; Juan Guillermo Prada
Journal:  Can Urol Assoc J       Date:  2017-12-22       Impact factor: 1.862

7.  Recommendations for Treating Males: An Ethical Rationale for the Inclusion of Testicular Self-Examination (TSE) in a Standard of Care.

Authors:  Michael J Rovito; Janna Manjelievskaia; James E Leone; Michael Lutz; Chase T Cavayero; David Perlman
Journal:  Am J Mens Health       Date:  2015-12-03

Review 8.  Emerging Therapeutic Targets for Male Germ Cell Tumors.

Authors:  Christian Daniel Fankhauser; Friedemann Honecker; Jörg Beyer; Peter Karl Bode
Journal:  Curr Oncol Rep       Date:  2015-12       Impact factor: 5.075

9.  Outcomes in stage I testicular seminoma: a population-based study of 9193 patients.

Authors:  Clair J Beard; Lois B Travis; Ming-Hui Chen; Nils D Arvold; Paul L Nguyen; Neil E Martin; Deborah A Kuban; Andrea K Ng; Karen E Hoffman
Journal:  Cancer       Date:  2013-04-30       Impact factor: 6.860

Review 10.  Chemotherapy-induced peripheral neurotoxicity and ototoxicity: new paradigms for translational genomics.

Authors:  Lois B Travis; Sophie D Fossa; Howard D Sesso; Robert D Frisina; David N Herrmann; Clair J Beard; Darren R Feldman; Lance C Pagliaro; Robert C Miller; David J Vaughn; Lawrence H Einhorn; Nancy J Cox; M Eileen Dolan
Journal:  J Natl Cancer Inst       Date:  2014-03-12       Impact factor: 13.506

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.